Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
NEW BRUNSWICK, N.J., June 14, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock.
Take Johnson & Johnson, for example. The New Brunswick, N.J.-based company makes everything from Band-Aids and Tylenol to knee implants and prescription drugs, all of which are fairly resistant to a global slowdown, Cramer said.
These Johnson & Johnson Mesh products were marketed to correct Stress Urinary Incontinence and Pelvic Organ Prolapse. Health Canada first licensed the products for sale and use in Canada on August 19, 1998.
An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
Analysts are starting to like Johnson & Johnson again. (Disclaimer: I have now exhausted my knowledge of markets.) What drives the value of companies these days, brand power (trademarks) or brain power (patents)?